SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group (SGM) is pushing late‑stage oncology drugs—its 35% survival‑boosting PD‑L1 inhibitor and 50%‑response CAR‑T—toward FDA approval, backed by Genentech and EU partnerships that could unlock major upside despite current losses…

SELLAS Life Sciences: Late‑stage oncology pipeline, strategic partnerships, and key Phase II/III milestones that could spark a share rally—investors watch for FDA/EMA designations and licensing deals.